Guggenheim raised the firm’s price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the “promising” preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the “relatively underwhelming” results from alixorexton in NT2 that were reported by Alkermes (ALKS).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals Announces Underwriting Agreement for ADS Offering
- Centessa Pharmaceuticals: Promising Market Position with ORX750’s Superior Efficacy and Potential
- Morgan Stanley sees Centessa’s ORX750 as ‘best-in-class’ after competitor data
- Midday Fly By: AMD sees acceleration, IBM unveils quantum processor
- Centessa rises 14.0%